Developing an effective lung cancer program in a community hospital setting.

Abstract:

:Lung cancer remains the number one cause of cancer-based mortality in men and women. The importance of proper lung cancer care outside of major academic centers cannot be overemphasized because the vast majority of lung cancer care occurs in community hospital settings. We have had the opportunity to develop a highly successful community hospital-based lung cancer program. Utilizing a multidisciplinary approach, we have achieved steadily improving survival rates that are much higher than those observed nationally for patients diagnosed with lung cancer. Key components of this successful program include: (1) a weekly multidisciplinary lung cancer case conference with medical doctor representatives from medical oncology, thoracic surgery, pulmonary medicine, radiology, radiation oncology, and nuclear medicine who discuss patient presentation, test results, treatment history, and plans for therapy; (2) thoracic surgeons skilled in minimally invasive video-assisted thoracoscopic surgery; (3) nurse navigator/coordinators to help patients through the process from detection to recovery and provide a personal bond that greatly improves patient satisfaction; (4) utilization of treatment guidelines for patient-specific treatment strategies; (5) formal continuing medical education; (6) an emphasis on early detection that includes consideration of computed tomography screening of former smokers; (6) a cancer center that allows for many services to be offered at a single location for patient convenience and to promote interdisciplinary care; and (7) access to research protocols. These components have helped us provide a quality lung cancer program in a community hospital setting that is associated with excellent clinical outcomes.

journal_name

Clin Lung Cancer

journal_title

Clinical lung cancer

authors

Fischel RJ,Dillman RO

doi

10.3816/CLC.2009.n.032

subject

Has Abstract

pub_date

2009-07-01 00:00:00

pages

239-43

issue

4

eissn

1525-7304

issn

1938-0690

pii

S1525-7304(11)70099-7

journal_volume

10

pub_type

杂志文章
  • Maintenance or Consolidation Therapy for Non--Small-Cell Lung Cancer: A Meta-Analysis Involving 5841 Subjects.

    abstract:INTRODUCTION:Maintenance therapy is a new treatment paradigm for advanced non-small-cell lung cancer (NSCLC). We conducted a meta-analysis to evaluate its clinical efficacy in NSCLC and compared the efficacy of chemotherapy, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), and other treatment ap...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,meta分析

    doi:10.1016/j.cllc.2015.01.002

    authors: Zhang C,Huang C,Wang J,Wang X,Li K

    更新日期:2015-09-01 00:00:00

  • Weekly paclitaxel in elderly patients (aged > or = 70 years) with advanced non-small-cell lung cancer: an alternative choice? Results of a phase II study.

    abstract:PURPOSE:Paclitaxel and platinum-based chemotherapy is considered to be a standard approach for locally advanced and metastatic non-small-cell lung cancer (NSCLC). In recent years, weekly paclitaxel has been widely used for its safety profile, especially in breast and ovarian cancer. Otherwise, only a few studies are av...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.3816/CLC.2008.n.043

    authors: Rossi D,Dennetta D,Ugolini M,Alessandroni P,Catalano V,Fedeli SL,Giordani P,Casadei V,Baldelli AM,Graziano F,Catalano G

    更新日期:2008-09-01 00:00:00

  • Systematic review of the cost-effectiveness of positron-emission tomography in staging of non--small-cell lung cancer and management of solitary pulmonary nodules.

    abstract::Implementation of positron-emission tomography (PET) is variable depending on jurisdiction in part due to uncertainty about cost-effectiveness. Our objective was to perform a systematic review describing cost-effectiveness of PET in staging of non-small-cell lung cancer (NSCLC) and management of solitary pulmonary nod...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.cllc.2011.09.002

    authors: Cao JQ,Rodrigues GB,Louie AV,Zaric GS

    更新日期:2012-05-01 00:00:00

  • Survival of Asian Females With Advanced Lung Cancer in the Era of Tyrosine Kinase Inhibitor Therapy.

    abstract:INTRODUCTION:We examined the effect of access to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy on survival for Asian female (AF) EGFR mutation-enriched patients with advanced lung adenocarcinoma. MATERIALS AND METHODS:We used the Surveillance Epidemiology and End Results database to s...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2016.08.008

    authors: Becker DJ,Wisnivesky JP,Grossbard ML,Chachoua A,Camidge DR,Levy BP

    更新日期:2017-01-01 00:00:00

  • The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.

    abstract::The combination of chemotherapy and radiation has been validated for the treatment of locally advanced non-small-cell lung cancer (NSCLC). However, the results are still unsatisfactory, and there is a need to improve current treatment. One approach is to use new agents that have the potential to enhance the efficacy o...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,评审

    doi:10.3816/clc.2005.s.011

    authors: Edelman MJ

    更新日期:2005-10-01 00:00:00

  • Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs.

    abstract:INTRODUCTION:We examined mutational testing of the epidermal growth factor gene (EGFR) and erlotinib treatment among veterans diagnosed with non-small-cell lung cancer in the United States Department of Veterans Affairs (VA). Our objectives were to identify the prevalence of clinically actionable EGFR mutations, to det...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2016.11.018

    authors: Lynch JA,Berse B,Chun D,Rivera D,Filipski KK,Kulich S,Viernes B,DuVall SL,Kelley MJ

    更新日期:2017-07-01 00:00:00

  • Nine-year Experience: Prophylactic Cranial Irradiation in Extensive Disease Small-cell Lung Cancer.

    abstract:BACKGROUND:In 2007, the European Organization for Research and Treatment of Cancer (EORTC) study (ClinicalTrials.gov identifier, NCT00016211) demonstrated a beneficial effect on overall survival (OS) with the use of prophylactic cranial irradiation (PCI) for extensive disease (ED) small-cell lung cancer (SCLC). Neverth...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2016.11.012

    authors: Bernhardt D,Adeberg S,Bozorgmehr F,Opfermann N,Hoerner-Rieber J,Repka MC,Kappes J,Thomas M,Bischoff H,Herth F,Heußel CP,Debus J,Steins M,Rieken S

    更新日期:2017-07-01 00:00:00

  • Targeted Tissue and Cell-Free Tumor DNA Sequencing of Advanced Lung Squamous-Cell Carcinoma Reveals Clinically Significant Prevalence of Actionable Alterations.

    abstract:BACKGROUND:Major guidelines do not recommend routine molecular profiling of lung squamous-cell carcinoma (LUSC) because the prevalence of actionable alterations is thought to be low. Increased utilization of next-generation sequencing (NGS), particularly with cell-free circulating tumor DNA, facilitates reevaluation of...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2018.08.020

    authors: Lam VK,Tran HT,Banks KC,Lanman RB,Rinsurongkawong W,Peled N,Lewis J,Lee JJ,Roth J,Roarty EB,Swisher S,Talasaz A,Futreal PA,Papadimitrakopoulou V,Heymach JV,Zhang J

    更新日期:2019-01-01 00:00:00

  • Second Primary Non-Small-Cell Lung Cancer After Head and Neck Cancer: A Population-Based Study of Clinical and Pathologic Characteristics and Survival Outcomes in 3597 Patients.

    abstract:INTRODUCTION:Retrospective studies have shown an increased risk of second primary lung cancer in patients with a history of head and neck cancer (HNC). No population-based study has examined the overall survival (OS) outcomes of patients with second primary non-small-cell lung cancer (NSCLC) after HNC comparison with p...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2019.02.017

    authors: Budnik J,DeNunzio NJ,Singh DP,Milano MT

    更新日期:2020-05-01 00:00:00

  • Treatment Response and Prophylactic Cranial Irradiation Are Prognostic Factors in a Real-life Limited-disease Small-cell Lung Cancer Patient Cohort Comprehensively Staged With Cranial Magnetic Resonance Imaging.

    abstract:INTRODUCTION:Prophylactic cranial irradiation (PCI) has proven to decrease the incidence of brain metastases (BMs), with a modest improvement in survival. PATIENTS AND METHODS:The impact of PCI was evaluated in 184 patients treated with chemoradiotherapy. PCI was applied to patients with disease with partial and compl...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2016.11.005

    authors: Eze C,Roengvoraphoj O,Niyazi M,Hildebrandt G,Fietkau R,Belka C,Manapov F

    更新日期:2017-07-01 00:00:00

  • A randomized, double-blind, phase III study of Docetaxel and Ramucirumab versus Docetaxel and placebo in the treatment of stage IV non-small-cell lung cancer after disease progression after 1 previous platinum-based therapy (REVEL): treatment rationale an

    abstract::This article describes the treatment rationale and study-related procedures for the A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small-Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy (REVEL) st...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1016/j.cllc.2012.06.007

    authors: Garon EB,Cao D,Alexandris E,John WJ,Yurasov S,Perol M

    更新日期:2012-11-01 00:00:00

  • Advancements in Small-cell Lung Cancer: The Changing Landscape Following IMpower-133.

    abstract::The treatment landscape of small-cell lung cancer is rapidly evolving. Results of the first-line randomized trial comparing etoposide/carboplatin/placebo with etoposide/carboplatin/atezolizumab (IMpower-133) were recently published, showing a longer progression-free survival and overall survival for patients receiving...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,评审

    doi:10.1016/j.cllc.2018.12.019

    authors: Pacheco J,Bunn PA

    更新日期:2019-05-01 00:00:00

  • Concurrent chemoradiotherapy for patients with postoperative recurrence of surgically resected non-small-cell lung cancer.

    abstract:BACKGROUND:A few reports have evaluated the outcomes of concurrent chemoradiotherapy (CRT) for patients with postoperative recurrence of non-small cell lung cancer (NSCLC). PATIENTS AND METHODS:From 2000 through 2011, 1237 consecutive patients with NSCLC underwent pulmonary resection at our institution. Of those, 280 ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2014.06.001

    authors: Takenaka T,Takenoyama M,Toyozawa R,Inamasu E,Yoshida T,Toyokawa G,Shiraishi Y,Hirai F,Yamaguchi M,Seto T,Ichinose Y

    更新日期:2015-01-01 00:00:00

  • Prevalence and clinical significance of incidental and clinically suspected venous thromboembolism in lung cancer patients.

    abstract:BACKGROUND:It is unclear what proportion of VTE events in lung cancer patients are incidentally discovered and whether incidental events affect mortality. PATIENTS AND METHODS:We conducted a retrospective cohort study of lung cancer patients seen at the University of Rochester between January 1, 2006 and December 31, ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2013.06.003

    authors: Connolly GC,Menapace L,Safadjou S,Francis CW,Khorana AA

    更新日期:2013-11-01 00:00:00

  • RELEVENT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma.

    abstract::Thymic epithelial tumors are rare malignancies. Thymic carcinoma represents about 20% of all thymic epithelial tumors and has aggressive behavior, with a greater tendency to metastatic spread. Thymic carcinoma is often diagnosed in advanced stages for which systemic treatment is the main therapeutic option. The associ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章,多中心研究

    doi:10.1016/j.cllc.2018.06.005

    authors: Imbimbo M,Vitali M,Fabbri A,Ottaviano M,Pasello G,Petrini I,Palmieri G,Berardi R,Zucali P,Ganzinelli M,Marabese M,Broggini M,Marino M,Trama A,Rulli E,Hollander L,Pruneri G,Torri V,Garassino MC

    更新日期:2018-09-01 00:00:00

  • A phase II study of topotecan in patients with relapsed small-cell lung cancer.

    abstract::An early phase II study of topotecan produced favorable results in a small number of untreated and previously treated patients with small-cell lung cancer (SCLC). This multicenter study was conducted in patients with relapsed SCLC at 19 medical institutions in Japan. Topotecan 1.0 mg/m2/day was administered for 5 cons...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.3816/clc.2003.n.002

    authors: Takeda K,Negoro S,Sawa T,Nakagawa K,Kawahara M,Isobe T,Kudoh S,Masuda N,Niitani H,Fukuoka M

    更新日期:2003-01-01 00:00:00

  • Role of topoisomerase I inhibitors in small-cell lung cancer.

    abstract::Lung cancer continues to be the leading cause of cancer-related death in the United States. Small-cell lung cancer constitutes 15%-20% of all cases of lung cancer. It is a chemosensitive disease with an overall response rate of 70%-90% in first-line treatment. However, the majority of patients relapse, and further tre...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.3816/clc.2001.n.010

    authors: Shihabi S,Belani CP

    更新日期:2001-05-01 00:00:00

  • Classifications of n2 non-small-cell lung cancer based on the number and rate of metastatic mediastinal lymph nodes.

    abstract:BACKGROUND:Subdivisions of N2 non-small-cell lung cancer (NSCLC) cases based on metastatic status of mediastinal and non-mediastinal lymph nodes have been proposed. This study aimed to evaluate N2 disease classification by mediastinal lymph nodes alone. PATIENTS AND METHODS:We reviewed 187 patients with NSCLC pN1-N2 w...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2013.04.012

    authors: Ito M,Yamashita Y,Tsutani Y,Misumi K,Harada H,Miyata Y,Okada M

    更新日期:2013-11-01 00:00:00

  • Comparing Outcomes of Patients With Early-Stage Non-Small-Cell Lung Cancer Treated With Stereotactic Body Radiotherapy Based on Frailty Status.

    abstract:INTRODUCTION:Frailty of surgical patients has been associated with worse outcomes. There is limited literature discussing frailty in patients with lung cancer treated with stereotactic body radiotherapy (SBRT). This study assesses the relationship between frailty and overall survival (OS), tumor control, and toxicity i...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2018.05.008

    authors: Raghavan G,Shaverdian N,Chan S,Chu FI,Lee P

    更新日期:2018-09-01 00:00:00

  • Mature results of a phase II trial of gemcitabine/paclitaxel given every 2 weeks in patients with advanced non-small-cell lung cancer.

    abstract:PURPOSE:This phase II study evaluated the efficacy and toxicity of gemcitabine/paclitaxel given every 2 weeks in patients with advanced-stage non-small-cell lung cancer. Treatment with 1 previous chemotherapy regimen was allowed. Patients received gemcitabine 3000 mg/m(2) intravenously over 30 minutes and paclitaxel 15...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.3816/CLC.2007.n.010

    authors: Wozniak AJ,Belzer K,Heilbrun LK,Kucuk O,Gadgeel S,Kalemkerian GP,Venkatramanamoorthy R,Kraut MJ

    更新日期:2007-03-01 00:00:00

  • Survival Disparities in Black Patients With EGFR-mutated Non-small-cell Lung Cancer.

    abstract:BACKGROUND:Little is known about the difference between black and non-black patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC), particularly regarding survival. We thus characterized the EGFR expression profile, clinical characteristics, and survival outcome in these patien...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2019.07.003

    authors: Cheng H,Hosgood HD,Deng L,Ye K,Su C,Sharma J,Yang Y,Halmos B,Perez-Soler R

    更新日期:2020-03-01 00:00:00

  • Results from a single institution phase II trial of concurrent docetaxel/carboplatin/radiotherapy followed by surgical resection and consolidation docetaxel/carboplatin in stage III non-small-cell lung cancer.

    abstract:BACKGROUND:The optimal treatment of locally advanced non-small-cell lung cancer (NSCLC) remains controversial. We hypothesized that using a trimodality approach in selected patients with stage IIIA/IIIB disease would be both feasible and efficacious with reasonable toxicity. PATIENTS/METHODS:We enrolled 13 patients wi...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2011.06.003

    authors: Das M,Donington JS,Murphy J,Kozak M,Eclov N,Whyte RI,Hoang CD,Zhou L,Le QT,Loo BW,Wakelee H

    更新日期:2011-09-01 00:00:00

  • Total videothoracoscopic lobectomy versus open thoracotomy for early-stage non small-cell lung cancer.

    abstract::Lobectomy remains the standard procedure for early-stage non small-cell lung cancer (NSCLC). Advances in minimally invasive surgery allow lobectomy to be performed by videothoracoscopy (VATSLOBE). The objective of this study was to compare open thoracotomy (OPENLOBE) to VATSLOBE in the treatment of early-stage NSCLC. ...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.3816/clc.2000.n.018

    authors: Luketich JD,Meehan MA,Landreneau RJ,Christie NA,Close JM,Ferson PF,Keenan RJ,Belani CP

    更新日期:2000-08-01 00:00:00

  • Presence of Even a Small Ground-Glass Component in Lung Adenocarcinoma Predicts Better Survival.

    abstract:BACKGROUND:While lepidic-predominant lung adenocarcinomas are known to have better outcomes than similarly sized solid tumors, the impact of smaller noninvasive foci within predominantly solid tumors is less clearly characterized. We tested the hypothesis that lung adenocarcinomas with even a small ground-glass opacity...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2017.06.020

    authors: Berry MF,Gao R,Kunder CA,Backhus L,Khuong A,Kadoch M,Leung A,Shrager J

    更新日期:2018-01-01 00:00:00

  • Lung cancer hormesis in high impact states where nuclear testing occurred.

    abstract:BACKGROUND:Hormesis is a favorable biological response to low toxin exposure. In the case of radiation, large doses are carcinogenic, but low doses might be protective. In the current study, we analyzed lung cancer incidence in high-impact radiation states where nuclear testing occurred and compared it with lung cancer...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2014.09.010

    authors: Lehrer S,Rosenzweig KE

    更新日期:2015-03-01 00:00:00

  • Utilization of Surgery and Its Impact on Survival in Patients With Early Stage Small-cell Lung Cancer in the United States.

    abstract:INTRODUCTION:For patients with T1 or T2 N0 M0 small-cell lung cancer (SCLC), lobectomy followed by chemotherapy is the standard of care. However, because of its tendency for early dissemination, patients are often treated with concurrent chemo-radiation without surgery. This study was conducted to evaluate the utilizat...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2019.07.013

    authors: Uprety D,Arjyal L,Vallatharasu Y,Bista A,Borgert A,Fitzsimmons AJ,Parsons BM

    更新日期:2020-03-01 00:00:00

  • Radiotherapy for stage III non-small-cell lung carcinoma in the elderly (age ≥ 70 years).

    abstract:BACKGROUND:Elderly patients are underrepresented in trials that establish definitive chemoradiotherapy as the standard of care for inoperable stage III non-small-cell lung carcinoma (NSCLC). This study analyzed radiotherapy treatment delivery and outcomes at our institution according to elderly (≥ 70 years old) or youn...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2013.05.001

    authors: Aridgides PD,Janik A,Bogart JA,Duffy S,Rosenbaum P,Gajra A

    更新日期:2013-11-01 00:00:00

  • Chemotherapy and Radiation Versus Chemotherapy Alone for Elderly Patients With N3 Stage IIIB NSCLC.

    abstract:BACKGROUND:Standard treatment for stage III non-small-cell lung cancer (NSCLC) is concurrent chemotherapy and radiation (chemo-RT). However, N3 stage IIIB disease portends a worse prognosis and the tolerability of chemo-RT in patients ≥70 years old is a concern. In this analysis, we evaluate the survival of patients wi...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2019.04.003

    authors: Qin A,Lusk E,Daignault-Newton S,Schneider BJ

    更新日期:2019-07-01 00:00:00

  • Association Between Environmental Tobacco Smoke Exposure and the Occurrence of EGFR Mutations and ALK Rearrangements in Never-smokers With Non-Small-cell Lung Cancer: Analyses From a Prospective Multinational ETS Registry.

    abstract:BACKGROUND:Molecular studies have demonstrated actionable driver oncogene alterations are more frequent in never-smokers with non-small-cell lung cancer (NSCLC). The etiology of these driver oncogenes in patients with NSCLC remains unknown, and environmental tobacco smoke (ETS) is a potential cause in these cases. MAT...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2017.01.005

    authors: Soo RA,Kubo A,Ando M,Kawaguchi T,Ahn MJ,Ou SI

    更新日期:2017-09-01 00:00:00

  • Analysis of single nucleotide polymorphisms and radiation sensitivity of the lung assessed with an objective radiologic endpoin.

    abstract:BACKGROUND:The primary objective of this study was to evaluate the association between radiation sensitivity of the lungs and candidate single nucleotide polymorphisms (SNP) in genes implicated in radiation-induced toxicity. METHODS:Patients with lung cancer who received radiation therapy (RT) had pre-RT and serial po...

    journal_title:Clinical lung cancer

    pub_type: 杂志文章

    doi:10.1016/j.cllc.2012.10.006

    authors: Kelsey CR,Jackson IL,Langdon S,Owzar K,Hubbs J,Vujaskovic Z,Das S,Marks LB

    更新日期:2013-05-01 00:00:00